同源康医药-B(02410)在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单

智通财经

01/29

智通财经APP讯，同源康医药-B(02410)公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。

甲磺酸艾多替尼片(TY-9591片)拟定的适应症为具有EGFR外显子19缺失(19DEL) 或外显子21(L858R)置换突变，并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2607702571"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607702571\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607702571?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-29 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607702571","market":"fut","top_or_hot":-1,"title":"同源康医药-B(02410)在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02410\">同源康医药-B</a>(02410)公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。</p><p>甲磺酸艾多替尼片(TY-9591片)拟定的适应症为具有EGFR外显子19缺失(19DEL) 或外显子21(L858R)置换突变，并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康医药-B(02410)在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康医药-B(02410)在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-29 17:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1399178.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，同源康医药-B(02410)公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。甲磺酸艾多替尼片(TY-9591片)拟定的适应症为具有EGFR外显子19缺失(19DEL) 或外显子21(L858R)置换突变，并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399178.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1399178.html","article_id":"2607702571","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607702571","pubTimestamp":1769677696,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，同源康医药-B(02410)公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。甲磺酸艾多替尼片(TY-9591片)拟定的适应症为具有EGFR外显子19缺失(19DEL) 或外显子21(L858R)置换突变，并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK1161":"生物科技","02410":"同源康医药-B","09939":"开拓药业-B"},"translate_title":"Tongyuankang Pharmaceutical-B (02410) Class 1 new drug Idotinib Mesylate Tablets under development was included in the list of priority review varieties by the Drug Evaluation Center of the State Medical Products Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5,"02410":1.5},"content_text":"智通财经APP讯，同源康医药-B(02410)公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。甲磺酸艾多替尼片(TY-9591片)拟定的适应症为具有EGFR外显子19缺失(19DEL) 或外显子21(L858R)置换突变，并伴有CNS转移的局部晚期或转移性NSCLC成人患者的一线治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}